Skip Navigation LinksHome > August 2012 - Volume 34 - Issue 6 > Thalidomide Therapy for Aggressive Histiocytic Lesions in th...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e3182580d6e
Clinical and Laboratory Observations

Thalidomide Therapy for Aggressive Histiocytic Lesions in the Pediatric Population

Bailey, Kelly M. MD, PhD; Castle, Valerie P. MD; Hummel, Jennifer M. MD; Piert, Morand MD; Moyer, Judith RN, PNNP; McAllister-Lucas, Linda M. MD, PhD

Collapse Box


Aggressive histiocytic lesions are uncommon in the pediatric population. These neoplasms occur in isolation or after therapy for other types of hematopoietic malignancy such as T-cell acute lymphoblastic leukemia. The etiology of these lesions is poorly understood, and no definitive standard of care has been established for patients with these diagnoses. Here, we report the success of thalidomide treatment for 2 subtypes of histiocytic proliferation—metastatic histiocytic sarcoma and extracutaneous juvenile xanthogranuloma—in pediatric patients. Our findings highlight the importance of considering thalidomide therapy in this unique and difficult to treat patient population.

Copyright © 2012 Wolters Kluwer Health, Inc. All rights reserved.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.